文献速递其他结缔组织病

细胞周期蛋白依赖性激酶4/6抑制剂对系统性硬化症小鼠模型皮肤纤维化的治疗作用

Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2022-03-23

本研究在系统性硬化症(SSc)患者皮肤成纤维细胞及HOCl和博来霉素诱导的小鼠皮肤纤维化模型中,观察CDK4/6抑制剂哌柏西利单用或联合TGFβR抑制剂galunisertib的作用;结果显示哌柏西利抑制成纤维细胞增殖及TGFβ诱导的肌成纤维细胞分化,减少小鼠皮肤厚度、胶原含量、成纤维细胞增殖和肌成纤维细胞数量,联合治疗有叠加抗纤维化效果;作者认为CDK4/6抑制剂可能成为SSc治疗新药。

要点

  • 哌柏西利抑制SSc患者皮肤成纤维细胞增殖及TGFβ诱导的肌成纤维细胞分化,且不抑制经典与非经典TGFβ信号。
  • 在小鼠皮肤纤维化模型中,CDK4/6抑制剂单药减少皮肤厚度、胶原含量、成纤维细胞增殖及肌成纤维细胞数量。
  • CDK4/6抑制剂与TGFβR抑制剂galunisertib联合具有叠加抗纤维化作用。

核心结论

  • 结果表明CDK4/6抑制剂单用或联合TGFβR抑制剂对皮肤纤维化有治疗作用,哌柏西利等CDK4/6抑制剂可能成为SSc治疗新药,与TGFβR抑制剂联用可能提高疗效。

研究设计与样本

  • 体外培养SSc患者皮肤成纤维细胞,在有或无TGFβ条件下用溴脱氧尿苷摄取实验、免疫荧光和免疫印迹分析检测哌柏西利对增殖和分化的影响。
  • 使用HOCl诱导和博来霉素诱导的小鼠皮肤纤维化模型,给予CDK4/6抑制剂单药或联合TGFβR抑制剂galunisertib治疗。

主要发现

  • 在细胞培养中加入CDK4/6抑制剂抑制人SSc皮肤成纤维细胞增殖及TGFβ诱导的肌成纤维细胞分化,且不抑制经典和非经典TGFβ信号。
  • 在小鼠皮肤纤维化模型中,CDK4/6抑制剂治疗降低皮肤厚度、胶原含量、真皮成纤维细胞增殖及肌成纤维细胞数量。
  • CDK4/6抑制剂与TGFβR抑制剂联合治疗产生叠加抗纤维化效果。
  • 机制上,CDK4/6抑制剂抑制细胞通讯网络因子2和钙黏蛋白11的表达。

临床怎么用

  • 作者认为CDK4/6抑制剂(包括本研究中使用的哌柏西利)可能成为治疗SSc的新药,与TGFβR抑制剂联用可能提高疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: One of the histologic characteristics of systemic sclerosis (SSc) is an increased number of dermal myofibroblasts, and transforming growth factor β (TGFβ) plays a crucial role in the promotion of myofibroblast differentiation from fibroblasts, leading to dermal fibrosis. This study was undertaken to 1) examine whether inhibition of the cell cycle with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor suppresses the proliferation of fibroblasts and their differentiation into myofibroblasts, and 2) assess the therapeutic effects of a CDK4/6 inhibitor, administered as monotherapy or in combination with a TGFβ receptor (TGFβR) inhibitor, on dermal fibrosis in murine models of SSc. METHODS: Fibroblasts obtained from the skin of patients with SSc were cultured in the presence or absence of TGFβ. The effects of palbociclib, a CDK4/6 inhibitor, on fibroblast proliferation and TGFβ-induced differentiation into myofibroblasts were examined using bromodeoxyuridine uptake assays as well as immunofluorescence and immunoblotting analyses. Murine models of HOCl- and bleomycin-induced dermal fibrosis were used to study the effect of a CDK4/6 inhibitor on dermal fibrosis, with the CDK4/6 inhibitor treatment administered as monotherapy or in combination with galunisertib, a TGFβR inhibitor. RESULTS: Addition of a CDK4/6 inhibitor to the cell cultures suppressed the proliferation of human dermal SSc fibroblasts and their TGFβ-induced differentiation into myofibroblasts, without inhibiting canonical and noncanonical TGFβ signals. In murine models of dermal fibrosis, treatment of mice with a CDK4/6 inhibitor decreased dermal thickness and collagen content, as well as dermal fibroblast proliferation and the numbers of myofibroblasts. Combination therapy with the CDK4/6 inhibitor and TGFβR inhibitor resulted in additive antifibrotic effects. Mechanistically, the CDK4/6 inhibitor suppressed the expression of cellular communication network 2 and cadherin-11, which are proteins that have important roles in the development and progression of fibrosis. CONCLUSION: Results of this study demonstrate the therapeutic effect of a CDK4/6 inhibitor on dermal fibrosis when administered as monotherapy or in combination with a TGFβR inhibitor. CDK4/6 inhibitors, including palbociclib used in the present study, may represent novel agents for the treatment of SSc, which, if used in combination with a TGFβR inhibitor, might result in increased efficacy.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Yamamoto A, Saito T, Hosoya T, et al. Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis. Arthritis Rheumatol. 2022. PMID: 34882985. doi:10.1002/art.42042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。